Tom 3, Nr 3 (2010)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2010-10-05
Wyświetlenia strony
482
Wyświetlenia/pobrania artykułu
9946
Metoda inaktywacji czynników chorobotwórczych w składnikach krwi
Journal of Transfusion Medicine 2010;3(3):112-119.
Streszczenie
Brak
Referencje
- Antoniewicz-Papis J, Woźniak J, Krzywdzińska A. Lymphocyte survival/activation in stored platelet concentrates following gamma-irradiation or pathogen reduction technology treatment. Vox Sang. 2010; 99(supl. 1): 3D-S10-02.
- Król D, Drybańska B, Zyla J, et al. Usefulness of plasma subjected to pathogen reduction for cryoprecipitate production. Vox Sang. 2010; 99(supl. 1): 239.
- Galuszka W, Bojarska E, Augustyniok Z. Infectious agents inactivation of human plasma with the theraflex methylene blue system. Vox Sang. 2010; 99(supl. 1): 246–247.
- Strauss Patko M. Routine fresh frozen plasma manufacture with pathogen inactivation by methylene blue (theraflex MB-Plasma). Vox Sang. 2010; 99(supl. 1): 253.
- Knuever-Hopf J, Schaefer W, Groener A. Human parvovirus in plasma is highly sensitive to methylene blue/light treatment. Vox Sang. 2010; 99(supl. 1): 240.
- Pohler P, Legmann J, Veneruso V. Lack of antibody formation to plasma and platelet neoantigens after transfusion of USCirradiated platelet concentrates in an autologous animal model. Vox Sang. 2010; 99(supl. 1): 255.
- Castrillo A, Arcas C. Martinez-R.N. In vitro quality of apheresis platelets treated with the theraflex uv-system for pathogen inactivation. Vox Sang. 2010; 99(supl. 1): 250.
- Löf H. Joelsson Saxner A., Knutson F. Pathogen inactivated platelets decrease transfusion reactions. Vox Sang. 2010; 99(supl. 1): 240–241.
- Lehmann C, Rummler S, Kummer C, et al. Pathogen inactivation of single donor plasma. Vox Sang. 2010; 99(supl. 1): 242.
- Saldado W, Le Yo, Perrault M. Process validation of the Intercept blood system™ for pathogen inactivation of apheresis plasma at a regional centee (efs-Centre Atantique). Vox Sang. 2010; 99(supl. 1): 254.
- Stanojkovic Z, Antic A. the influence of riboflavin and ultrafiolet light on quality of fresh frozen plasma. Vox Sang. 2010; 99: supl.
- Maia S, Dobao ML, Queiros L. Mirasol ® treated plasma evaluation at Centro Regional de Sangue do Porto. Vox Sang. 2010; 99(supl. 1): 245.
- Maia S, Cardoso M, Oliviera N. Flexibility of the system Mirasol PRT to adapt to a blood bank routine-the experience of CRSP, Porto. Vox Sang. 2010; 99(supl. 1): 246.
- Ettinger A, Miklauz MM, Hendrix BK. Mirasol-treated plasma protein quality after 1 year of storage AT -18°C. Vox Sang. 2010; 99(supl. 1): 241–242.
- Lachert E, Antoniewicz-Papis J, Dzieciątkowska O. Quality control of riboflavin and UV light treated plasma using the Mirasol PRT system. Vox Sang. 2010; 99(supl. 1): 255.
- Reddy L, Marschner S, Doane S. Room temperature storage of whole blood treated with the Mirasol System. Vox Sang. 2010; 99(supl. 1): 243–244.
- AuBuchon JP. Current status of pathogen inactivation methods. ISBT Science Series. 2010; 5(n1): 125–133.
- Heger A, Bailey A, Gregori L. Octaplas L.G. improvement of biochemical quality and pathogen safety. Vox Sang. 2010; 99(supl. 1): 254.
- Gathof BS, Tauszig ME, Picker SM. Pathogen inactivation/reduction of platelet concentrates: turning theory into practice. ISBT Science Series. 2010; 5(n1): 114–119.
- Heiden M, Seitz R. Pathogen inactivation - regulators aspects. ISBT Science Series. 2010; 5(n1): 279–281.
